Allison J. Kaeding

Hematology | Oncology

825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Journal: Blood

Published: July 24, 2025

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

Journal: Blood

Published: July 24, 2025

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies.

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies.

Journal: Cancers

Published: November 01, 2021

Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.

Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.

Journal: Blood advances

Published: February 03, 2021

Showing 1-4 of 4

Last Updated: 09/26/2026